» Authors » Thomas W Donner

Thomas W Donner

Explore the profile of Thomas W Donner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 307
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Husni H, Khan S, Alghaieb B, Abusamaan M, Donner T, Hamrahian A
Clin Case Rep . 2022 Mar; 10(3):e05650. PMID: 35356161
Insulinomas are rare neuroendocrine pancreatic tumors that can be associated with severe episodes of hypoglycemia, leading to significant morbidity and mortality. These tumors are often difficult to localize, and hypoglycemia...
2.
Shapiro A, Thompson D, Donner T, Bellin M, Hsueh W, Pettus J, et al.
Cell Rep Med . 2022 Jan; 2(12):100466. PMID: 35028608
These preliminary data from an ongoing first-in-human phase 1/2, open-label study provide proof-of-concept that pluripotent stem cell-derived pancreatic endoderm cells (PEC-01) engrafted in type 1 diabetes patients become islet cells...
3.
Saxena A, Yagita H, Donner T, Hamad A
Front Immunol . 2017 Apr; 8:402. PMID: 28439273
Fas ligand drives insulitis in the non-obese diabetic mouse model of type 1 diabetes (T1D) and negatively regulates IL-10-producing (IL-10) CD5 B cells in pancreata. Relevance of these phenomena to...
4.
Joseph J, Donner T
Vasc Health Risk Manag . 2015 Feb; 11:107-16. PMID: 25657589
Cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus. Hyperinsulinemia is associated with increased cardiovascular risk, but the effects of exogenous insulin on cardiovascular disease progression...
5.
Aronson R, Gottlieb P, Christiansen J, Donner T, Bosi E, Bode B, et al.
Diabetes Care . 2014 Jul; 37(10):2746-54. PMID: 25011949
Objective: Previous studies demonstrated that the anti-CD3 monoclonal antibody otelixizumab, administered at a total dose of 48-64 mg, can slow the loss of C-peptide in recent-onset type 1 diabetes patients,...
6.
7.
Bach R, Brooks M, Lombardero M, Genuth S, Donner T, Garber A, et al.
Circulation . 2013 Jul; 128(8):785-94. PMID: 23857320
Background: Rosiglitazone improves glycemic control for patients with type 2 diabetes mellitus, but there remains controversy regarding an observed association with cardiovascular hazard. The cardiovascular effects of rosiglitazone for patients...
8.
Joshi P, Kalyani R, Blumenthal R, Donner T
Am J Cardiol . 2012 Oct; 110(9 Suppl):32B-42B. PMID: 23062565
Macrovascular complications of type 2 diabetes mellitus (DM) are primarily driven by the combination of underlying atherosclerosis and propensity for thrombosis. Prevention of macrovascular complications in DM relies on therapies...
9.
Donner T, Magder L, Zarbalian K
Nutr Res . 2010 Dec; 30(12):801-6. PMID: 21147362
Oral d-tagatose (d-tag) attenuates the rise in plasma glucose during an oral glucose tolerance test in subjects with type 2 diabetes mellitus (DM) and reduces food intake in healthy human...
10.
Alon G, Conroy V, Donner T
Physiother Res Int . 2010 Nov; 16(2):81-91. PMID: 21110414
Background And Purpose: This study tested the safety and ability of subjects with chronic hemiplegia to tolerate intensive training using a motorized cycle combined with functional electrical stimulation (FES) system....